| abstract |
The purpose of the invention is to increase the therapeutic activity of oncolytic NDV. This problem is solved using the Newcastle disease virus containing recombinant nucleic acid, in which the nucleic acid encodes a binding protein that has therapeutic activity in the expression of a virus-infected tumor cell. Binding proteins belong to the following group: a natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or its modified version, a peptide ligand, an antibody molecule and its derivatives, or an antibody-like molecule such as ankyrin repeating molecules or their derivatives. |